Annual Changes to the NASDAQ Biotechnology Index
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Inovio Pharma (INO) Appoints New VP of Clinical Development, Oncology
December 17, 2014 8:00 AM ESTInovio Pharma (NASDAQ: INO) announced the appointment of Zane Yang, M.D. as Vice President, Clinical Development, Oncology. In this position, he will be responsible for advancing Inovio's oncology portfolio of DNA immunotherapies through clinical trials to commercialization. He will report to Dr. Mark Bagarazzi, Inovio's Chief Medical Officer.
Inovio is planning a phase III trial for its immunotherapy for a pre-cancer, known as cervical... More
Alimera Sciences (ALIM) Closes $50M Financing Arrangement with Deerfield
December 15, 2014 8:59 AM ESTAlimera Sciences (Nasdaq: ALIM) announced that it has closed its offering of Series B Preferred Stock with Deerfield Management and certain of its affiliates (Deerfield). Alimera issued Deerfield an aggregate of 8,291.873 shares of Series B Preferred Stock for a purchase price of $6,030.00 per share, or an aggregate purchase price of approximately $50.0 million. Each share of Series B Preferred Stock is convertible into 1,000 shares of Alimera's common stock at any time at the option of the holder, provided that the... More
